SCHEMBL5879136

SCHEMBL5879136

Cn1c(=O)c2c3c(=O)[nH]c(=O)c3c3[nH]c4ncccc4c3c2c1=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 1/20 0.49
PARP1 P09874 1/20 0.49
CHEK1 O14757 1/20 0.45
FEN1 P39748 1/20 0.44
PDK2 Q15119 1/20 0.43
MAPT P10636 1/20 0.42
ALDH1A1 P00352 2/20 0.42
CDK4 P11802 1/20 0.42
CCND1 P24385 1/20 0.42
KDM4E B2RXH2 3/20 0.41
HTT P42858 1/20 0.41
POLB P06746 1/20 0.41
PKM P14618 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
LOXL3 P58215 1/20 0.40
LOXL2 Q9Y4K0 1/20 0.40
GABRA1 P14867 1/20 0.40
GABRG2 P18507 1/20 0.40
GABRB3 P28472 1/20 0.40
GABRA5 P31644 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5879174 0.88 PARP1 (0.56) AURKAPARP1CHEK1FEN1PDK2
SCHEMBL5879135 0.78 CHEK1 (0.76) PARP1CHEK1MAPTALDH1A1CDK4
SCHEMBL5879158 0.75 CHEK1 (0.71) PARP1CHEK1MAPTALDH1A1CDK4
SCHEMBL1713792 0.71 FEN1 (0.66) AURKAPARP1FEN1MAPTALDH1A1
SCHEMBL7011325 0.69 MAPT (0.64) FEN1MAPTALDH1A1KDM4EHTT
SCHEMBL5879141 0.68 CHEK1 (0.59) PARP1CHEK1MAPTALDH1A1CDK4
SCHEMBL12396544 0.67 AURKA (0.65) AURKAPARP1CHEK1FEN1PDK2
SCHEMBL30322758 0.67 AURKA (0.65) AURKAPARP1CHEK1FEN1PDK2
SCHEMBL6531057 0.67 PARP1 (1.00) AURKAPARP1FEN1ALDH1A1KDM4E
SCHEMBL29368378 0.66 PARP1 (0.56) AURKAPARP1CHEK1FEN1PDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7151108-B2 Anticarcinogenic, antiproliferative, and antitumor agents LES LABORATORIES SERVIER (FR) 2006-12-19 US disclosed
EP-1411057-B1 [3,4-a:3,4-c]carbazole derivatives, process for their preparation and pharmaceutical compositions containing them SERVIER LAB (FR) 2005-04-27 EP disclosed
US-20040077672-A1 Anticarcinogenic, antiproliferative, and antitumor agents LES LABORATOIRES SERVIER (FR) 2004-04-22 US disclosed
EP-1411057-A1 [3,4-a:3,4-c]carbazole derivatives, process for their preparation and pharmaceutical compositions containing them Les Laboratoires Servier (FR) 2004-04-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077672-A1 Anticarcinogenic, antiproliferative, and antitumor agents XDH, TOP2A, TOP1 AURKA 2868/4885PARP1 120/4885CHEK1 943/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.